Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies.
The adverse impact of cytomegalovirus (CMV) infection after solid organ transplantion is currently believed to be mediated primarily by its immunomodulatory effects. There is a large body of evidence showing that both CMV disease and asymptomatic viremia are independent risk factors for the development of allograft rejection. The aim of this article is to summarize mechanisms whereby CMV is involved in the development and progression of allograft rejection, with particular emphasis on renal transplant recipients. The article will also address the potential of anti-CMV preventive protocols designed to favorably affect the incidence of allograft rejection.
Reischig
Tomás
T
Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 301 60 Pilsen, Czech Republic. reischig@fnplzen.cz
D000998:Antiviral Agents / Q000627:therapeutic use*; D018890:Chemoprevention; D003587:Cytomegalovirus / Q000187:drug effects; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*
D000998:Antiviral Agents